Accept Refuse

EUR-Lex Access to European Union law

This document is an excerpt from the EUR-Lex website

Document 52014PC0319

Proposal for a REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL to avoid trade diversion into the European Union of certain key medicines (codification)

COM/2014/0319 final - 2014/0165 (COD)

No longer in force, Date of end of validity: 11/05/2016

Brussels, 28.5.2014

COM(2014) 319 final

2014/0165(COD)

Proposal for a

REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

to avoid trade diversion into the European Union of certain key medicines (codification)


EXPLANATORY MEMORANDUM

1.In the context of a people’s Europe, the Commission attaches great importance to simplifying and clarifying the law of the so as to make it clearer and more accessible to citizens, thus giving them new opportunities and the chance to make use of the specific rights it gives them.

This aim cannot be achieved so long as numerous provisions that have been amended several times, often quite substantially, remain scattered, so that they must be sought partly in the original instrument and partly in later amending ones. Considerable research work, comparing many different instruments, is thus needed to identify the current rules.

For this reason a codification of rules that have frequently been amended is also essential if the law is to be clear and transparent.

2.On 1 April 1987 the Commission decided 1 to instruct its staff that all acts should be codified after no more than ten amendments, stressing that this is a minimum requirement and that departments should endeavour to codify at even shorter intervals the texts for which they are responsible, to ensure that their provisions are clear and readily understandable.

3.The Conclusions of the Presidency of the Edinburgh European Council (December 1992) confirmed this 2 , stressing the importance of codification as it offers certainty as to the law applicable to a given matter at a given time.

Codification must be undertaken in full compliance with the normal procedure for the adoption of acts of the Union.

Given that no changes of substance may be made to the instruments affected by codification, the European Parliament, the Council and the Commission have agreed, by an interinstitutional agreement dated 20 December 1994, that an accelerated procedure may be used for the fast-track adoption of codification instruments.

4.The purpose of this proposal is to undertake a codification of Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines 3 . The new Regulation will supersede the various acts incorporated in it 4 ; this proposal fully preserves the content of the acts being codified and hence does no more than bring them together with only such formal amendments as are required by the codification exercise itself.

5.The codification proposal was drawn up on the basis of a preliminary consolidation, in 22 official languages, of Regulation (EC) No 953/2003 and the instruments amending it, carried out by the Publications Office of the European Union, by means of a data-processing system. Where the Articles have been given new numbers, the correlation between the old and the new numbers is shown in a table set out in Annex VII to the codified Regulation.



ê 953/2003 (adapted)

2014/0165 (COD)

Proposal for a

REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

to avoid trade diversion into the European Union of certain key medicines (codification)

THE EUROPEAN PARLIAMENT AND THE COUNCIL OF THE EUROPEAN UNION,

Having regard to the Treaty Ö on the Functioning of the European Union Õ , and in particular Article Ö 207(2) Õ thereof,

Having regard to the proposal from the European Commission,

After transmission of the draft legislative act to the national Parliaments,

Having regard to the opinion of the European Economic and Social Committee 5 ,

Acting in accordance with the ordinary legislative procedure,

Whereas:

ê 

(1)Council Regulation (EC) No 953/2003 6  has been substantially amended several times 7 . In the interests of clarity and rationality, that Regulation should be codified.

ê 953/2003 recital 4 (adapted)

(2)Many of the poorest developing countries are in urgent need of access to affordable essential medicines for Ö the Õ treatment of communicable diseases. Those countries are heavily dependant on imports of medicines as local manufacturing is scarce.

ê 953/2003 recital 5

(3)Price segmentation between developed country markets and the poorest developing country markets is necessary to ensure that the poorest developing countries are supplied with essential pharmaceutical products at heavily reduced prices. Therefore, those heavily reduced prices cannot be understood as a reference for the price to be paid for the same products in developed country markets.

ê 953/2003 recital 6

(4)Legislative and regulatory instruments are in place in most developed countries to prevent importation, in certain circumstances, of pharmaceutical products, but these instruments risk becoming insufficient where substantial volumes of heavily discounted pharmaceuticals are sold to the poorest developing country markets and the economic interest in trade diversion into high priced markets therefore may increase significantly.

ê 953/2003 recital 7

(5)There is a need to encourage the pharmaceutical producers to make pharmaceutical products available at heavily reduced prices in significantly increased volumes by ensuring through this Regulation that these products remain on those markets. Donations of pharmaceutical products and products sold under contracts awarded in response to competitive tenders from national governments or international procurement bodies, or under a partnership agreed between the manufacturer and the government of a country of destination may qualify under this Regulation on equal conditions, bearing in mind that donations are not contributing to the improvement of access to these products on a sustainable basis.

ê 953/2003 recital 8 (adapted)

(6)For the purpose of this Regulation, it is necessary to Ö provide for Õ a procedure which identifies the products, countries and diseases covered by this Regulation.

ê 953/2003 recital 9 (adapted)

(7)This Regulation serves the purpose of preventing tiered priced products from being imported into the Ö  Õ . Exemptions are laid down for certain situations under the strict provision that it is ensured that the final destination of the products in question is one of the countries listed in Annex II.

ê 953/2003 recital 10

(8)Manufacturers of tiered priced products must differentiate the appearance of tiered priced products to facilitate the task of identifying them.

ê 953/2003 recital 11

(9)It will be appropriate to review the lists of the diseases and the countries of destination covered by this Regulation, as well as the formulae used to identify tiered priced products in the light, inter alia, of the experience gained from its application.

ê 953/2003 recital 13 (adapted)

(10)With regard to tiered priced products contained in travellers' personal luggage for personal use, the same rules as set out in Regulation (EU) No 608/2013 of the European Parliament and of the Council 8  apply.

ê 953/2003 recital 14

(11)Where tiered priced products have been seized under this Regulation, the competent authority may, in accordance with national legislation and with a view to ensuring that the intended use is made of the seized products to the full benefit of the countries listed in Annex II, decide to make them available for humanitarian purposes in those countries. In the absence of such decision, the seized products should be destroyed.

ê 38/2014 Art. 1 and Annex .3 (adapted)

(12) In order to add products to the list of products covered by Ö this Õ Regulation, the power to adopt acts in accordance with Article 290 of the Treaty should be delegated to the Commission in order to amend the Annexes to Ö this Õ Regulation. It is of particular importance that the Commission carry out appropriate consultations during its preparatory work, including at expert level. The Commission, when preparing and drawing up delegated acts, should ensure a simultaneous, timely and appropriate transmission of relevant documents to the European Parliament and to the Council,

ê 953/2003 (adapted)

HAVE ADOPTED THIS REGULATION:

Article 1

1. This Regulation lays down:

(a)the criteria for establishing what is a tiered priced product;

(b)the conditions under which the customs authorities shall take action;

(c)the measures which shall be taken by the competent authorities in the Member States.

2. For the purposes of this Regulation:

(a)‘tiered priced product’ means any pharmaceutical product used in the prevention, diagnosis and treatment of a disease referred to in Annex IV which is priced in accordance with one of the optional price calculations set out in Article 3, verified by the Commission or an independent auditor as provided for in Article 4 and entered in the list of tiered priced products set out in Annex I;

(b)‘countries of destination’ are those countries listed in Annex II;

(c)‘competent authority’ means an authority designated by a   to determine whether goods suspended by the customs authorities in the respective are tiered priced products and to give instructions depending on the outcome of the review.

Article 2

1. It shall be prohibited to import into the Ö Union Õ tiered priced products for the purposes of release for free circulation, re-export, placing under suspensive procedures or placing in a free zone or free warehouse.

2. The following shall be exempted from the prohibition regarding tiered priced products as set out in paragraph 1:

(a)re-export to countries of destination;

(b)placing under a transit or customs warehouse procedure or in a free zone or free warehouse for the purpose of re-export to a country of destination.

Article 3

The tiered price referred to in Article 4(2)(b) shall, at the option of the applicant, be either:

(a)no higher than the percentage set out in Annex III of the weighted average ex factory price charged by a manufacturer in markets Ö of the Organisation for Economic Co-operation and Development (OECD) Õ for the same product at the time of application; or

(b)a manufacturer's direct production costs, with the addition of a maximum percentage which is set out in Annex III.

Article 4

1. In order for products to benefit from this Regulation, manufacturers or exporters of pharmaceutical products shall submit applications to the Commission.

2. Any application addressed to the Commission shall contain the following information:

(a)the product name and active ingredient of the tiered priced product and sufficient information to verify which disease it is preventing, diagnosing or treating;

(b)the price offered in relation to either of the optional price calculations set out in Article 3 in sufficient detail to enable verification. Instead of submitting such detailed information, the applicant may submit a certificate issued by an independent auditor, stating that the price has been verified and corresponds to one of the criteria set out in Annex III. The independent auditor is appointed in agreement between the manufacturer and the Commission. Any information submitted by the applicant to the auditor shall remain confidential;

(c)the country or countries of destination to which the applicant intends to sell the product concerned;

(d)the code number based on the Combined Nomenclature as set out in Annex I to Council Regulation (EEC) No 2658/87 9 and, where appropriate, supplemented by TARIC subdivisions, to identify unambiguously the goods concerned;

(e)any measures taken by the manufacturer or exporter to make the tiered priced product easily distinguishable from identical products offered for sale Ö within Õ the Ö  Õ .

ê 38/2014 Art. 1 and Annex .3(1) (adapted)

3. Where the Commission determines that a product fulfils the requirements set out in this Regulation, the Commission shall be empowered to adopt delegated acts in accordance with Article 5(5) to add the product concerned to Annex I at the next following update. The Commission shall inform the applicant of its decision within 15 days of its adoption thereof.

Where a delay in the addition of a product to Annex I would cause a delay in responding to an urgent need of access to affordable essential medicines in a developing country, and therefore imperative grounds of urgency so require, the procedure provided for in Article 6 shall apply to delegated acts adopted pursuant to the first subparagraph.

ê 953/2003 (adapted)

4. If an application is not sufficiently detailed for review as to substance, the Commission shall Ö request Õ the applicant Ö in writing Õ to submit such missing information. If the applicant does not complete the application within the time period set out in that Ö written request Õ , the application shall be null and void.

5. If the Commission finds that the application does not fulfil the criteria set out in this Regulation, the application shall be rejected and the applicant shall be informed within 15 days of the date of the decision. Nothing shall prevent the applicant from submitting a modified application for the same product.

6. Products destined to be donated to recipients in one of the countries listed in Annex II may be notified accordingly for approval and insertion in Annex I.

7. Annex I shall be updated every second month by the Commission.

ê 38/2014 Art. 1 and Annex .3(1) (adapted)

8. The Commission shall be empowered to adopt delegated acts in accordance with Article 5(6) to Ö amend Õ Annexes II, III and IV where necessary in order to revise the list of diseases, the countries of destination covered by this Regulation as well as the formulae used to identify tiered priced products, in the light of the experience gained from its application or to respond to a health crisis.

ê 38/2014 Art. 1 and Annex .3(2)

Article 5

1. The power to adopt delegated acts is conferred on the Commission subject to the conditions laid down in this Article.

2. The power to adopt delegated acts referred to in Article 4 shall be conferred on the Commission for a period of five years from 20 February 2014. The Commission shall draw up a report in respect of the delegation of power not later than nine months before the end of the five-year period. The delegation of power shall be tacitly extended for periods of an identical duration, unless the European Parliament or the Council opposes such extension not later than three months before the end of each period.

3. The delegation of power referred to in Article 4 may be revoked at any time by the European Parliament or by the Council. A decision to revoke shall put an end to the delegation of power specified in that decision. It shall take effect the day following the publication of the decision in the Official Journal of the European Union or at a later date specified therein. It shall not affect the validity of any delegated acts already in force.

4. As soon as it adopts a delegated act, the Commission shall notify it simultaneously to the European Parliament and to the Council.

5. A delegated act adopted pursuant to Article 4(3) shall enter into force only if no objection has been expressed either by the European Parliament or the Council within a period of two months of notification of that act to the European Parliament and the Council or if, before the expiry of that period, the European Parliament and the Council have both informed the Commission that they will not object. That period shall be extended by two months at the initiative of the European Parliament or of the Council.

6. A delegated act adopted pursuant to Article 4(8) shall enter into force only if no objection has been expressed either by the European Parliament or the Council within a period of two months of notification of that act to the European Parliament and the Council or if, before the expiry of that period, the European Parliament and the Council have both informed the Commission that they will not object. That period shall be extended by four months at the initiative of the European Parliament or of the Council.

ê 38/2014 Art. 1 and Annex .3(3)

Article 6

1. Delegated acts adopted under this Article shall enter into force without delay and shall apply as long as no objection is expressed in accordance with paragraph 2. The notification of a delegated act to the European Parliament and to the Council shall state the reasons for the use of the urgency procedure.

2. Either the European Parliament or the Council may object to a delegated act in accordance with the procedure referred to in Article 5(5) and (6). In such a case, the Commission shall repeal the act without delay following the notification of the decision to object by the European Parliament or by the Council.

ê 953/2003 (adapted)

Article 7

A product approved as a tiered priced product and inserted in Annex I shall remain on that list for as long as the conditions set out in Article 4 are fulfilled and annual sales reports have been submitted to the Commission in accordance with Article 12. The applicant must submit information to the Commission on any change which has occurred with respect to the scope or conditions set out in Article 4 in order to ensure that these requirements are met.

Article 8

A permanent logo, as set out in Annex V, shall be affixed on any packaging or product and any document used in connection with the approved product sold at tiered prices to countries of destination. This applies as long as the tiered priced product concerned remains listed in Annex I.

Article 9

1. Where there is reason to suspect that, contrary to the prohibition Ö provided for Õ in Article 2, tiered priced products will be imported into the Ö Union Õ , customs authorities shall suspend the release of, or detain, the products concerned for the time necessary to obtain a decision of the competent authorities on the character of the merchandise. The period of suspension or detention shall not exceed 10 working days unless special circumstances apply, in which case the period may be extended by a maximum of 10 working days. Upon expiry of this period, the products shall be released, provided that all customs formalities have been complied with.

2. It shall be sufficient reason for the customs authorities to suspend the release of, or detain, products if there is sufficient information available to consider that the product in question is tiered priced.

3. The competent authority in the Member State concerned and the manufacturer or exporter mentioned in Annex I shall be informed without delay of the suspended release or detention of the products and shall receive all information available with respect to the products concerned. Due account shall be taken of national provisions on the protection of personal data, commercial and industrial secrecy and professional and administrative confidentiality. The importer, and where appropriate, the exporter, shall be given ample opportunity to supply the competent authority with the information which it deems appropriate regarding the products.

4. The procedure of suspension or detention of the goods is carried out at the expense of the importer. If it is not possible to recover these expenses from the importer, they may, in accordance with national legislation, be recovered from any other person responsible for the attempted illicit importation.

Article 10

1. If products suspended for release or detained by customs authorities are recognised by the competent authority as tiered priced products under this Regulation, the competent authority shall ensure that those products are seized and disposed of in accordance with national legislation. These procedures are carried out at the expense of the importer. If it is not possible to recover these expenses from the importer, they may, in accordance with national legislation, be recovered from any other person responsible for the attempted illicit importation.

2. Where products suspended for release or detained by customs authorities subsequent to further control by the competent authority are found not to qualify as tiered priced products under this Regulation, the customs authority shall release the products to the consignee, provided that all customs formalities have been complied with.

3. The competent authority shall inform the Commission of all decisions adopted pursuant to this Regulation.

Article 11

This Regulation shall not apply to goods of a non-commercial nature contained in travellers' personal luggage for personal use within the limits laid down in respect of relief from customs duty.

Article 12

1. The Commission shall monitor on an annual basis the volumes of exports of tiered priced products listed in Annex I and exported to the countries Ö of destination Õ on the basis of information provided to it by pharmaceutical manufacturers and exporters. For this purpose a standard form will be issued by the Commission. Manufacturers and exporters must submit such sales reports annually for each tiered priced product to the Commission on a confidential basis.

ê 38/2014 Art. 1 and Annex .3(4)

2. The Commission shall report biennially to the European Parliament and to the Council on the volumes exported under tiered prices, including on the volumes exported within the framework of a partnership agreement agreed between the manufacturer and the government of a country of destination. The report shall examine the scope of countries and diseases and general criteria for the implementation of Article 3.

3. The European Parliament may, within one month of submission of the Commission's report, invite the Commission to an ad hoc meeting of its responsible committee to present and explain any issues related to the application of this Regulation.

4. No later than six months from the date of submission of the report to the European Parliament and to the Council, the Commission shall make the report public.

ê 953/2003

Article 13

1. The application of this Regulation shall in no circumstances interfere with procedures laid down in Directive 2001/83/EC of the European Parliament and of the Council 10 and Regulation (EC) No 726/2004 of the European Parliament and of the Council 11 .

2. This Regulation shall not interfere with intellectual property rights or rights of intellectual property owners.

ê

Article 14

Regulation (EC) No 953/2003 is repealed.

References to the repealed Regulation shall be construed as references to this Regulation and shall be read in accordance with the correlation table in Annex VII.

ê 953/2003 (adapted)

Article 15

This Regulation shall enter into force on the Ö twentieth Õ day following Ö that of Õ its publication in the Official Journal of the European Union.

This Regulation shall be binding in its entirety and directly applicable in all Member States.

Done at Brussels,

For the European Parliament    For the Council

The President    The President

(1) COM(87) 868 PV.
(2) See Annex 3 to Part A of the Conclusions.
(3) Entered in the legislative programme for 2014.
(4) See Annex VI to this proposal.
(5) OJ C […], […], p. […].
(6) Council Regulation (EC) No 953/2003 of 26 May 2003 to avoid trade diversion into the European Union of certain key medicines (OJ L 135, 3.6.2003, p. 5).
(7) See Annex VI.
(8) Regulation (EU) No 608/2013 of the European Parliament and of the Council of 12 June 2013 concerning customs enforcement of intellectual property rights and repealing Council Regulation (EC) No 1383/2003 (OJ L 181, 29.6.2013, p. 15).
(9) Council Regulation (EEC) No 2658/87 of 23 July 1987 on the tariff and statistical nomenclature and on the Common Customs Tariff (OJ L 256, 7.9.1987, p. 1).
(10) Directive 2001/83/EC of the European Parliament and of the Council of 6 November 2001 on the Community code relating to medicinal products for human use (OJ L 311, 28.11.2001, p. 67).
(11) Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Community procedures for the authorisation and supervision of medicinal products for human and veterinary use and establishing a European Medicines Agency (OJ L 136, 30.4.2004, p. 1).
Top

Brussels, 28.5.2014

COM(2014) 319 final

ANNEXES

to the

proposal for a

REGULATION OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL

to avoid trade diversion into the European Union of certain key medicines (codification)


ê 953/2003

ANNEX I

LIST OF TIERED PRICED PRODUCTS

ê 1662/2005 Art. 1 and Annex (adapted)

Product

Manufacturer/exporter

Country of destination

Distinctive features

Date of approval

CN/TARIC code 1

TRIZIVIR

750 mg × 60

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

Afghanistan

Angola

Armenia

Azerbaijan

Bangladesh

Benin

Bhutan

Botswana

Burkina Faso

Burundi

Cambodia

Cameroon

Cape Verde

Central African Republic

Chad

Comoros

Congo

Côte d’Ivoire

Ö Democratic Republic of the Congo Õ

Djibouti

Equatorial Guinea

Eritrea

Ethiopia

Gambia

Ghana

Guinea

Guinea- Bissau

Haiti

Honduras

India

Indonesia

Kenya

Kiribati

Ö Kyrgyzstan Õ

Ö Laos Õ

Lesotho

Liberia

Madagascar

Malawi

Maldives

Mali

Mauritania

Moldova

Mongolia

Mozambique

Myanmar/Burma

Namibia

Nepal

Nicaragua

Niger

Nigeria

Ö North Korea Õ

Pakistan

Rwanda

Samoa

São Tomé and Principe

Senegal

Sierra Leone

Solomon Islands

Somalia

South Africa

Sudan

Swaziland

Tajikistan

Tanzania

Ö Timor-Leste Õ

Togo

Tuvalu

Uganda

Vanuatu

Yemen

Zambia

Zimbabwe

Distinctive access pack — trilingual text

19.4.2004

30049019

EPIVIR

150 mg × 60

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

Distinctive access pack — trilingual text — red tablets

30049019

RETROVIR

250 mg × 40

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

General export pack (blue) not used in EU.

French hospital pack — Francophone markets

19.4.2004

30049019

RETROVIR

300 mg × 60

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

General export pack (blue) not used in EU.

French hospital pack — Francophone markets

19.4.2004

30049019

RETROVIR

100 mg × 100

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

General export pack (blue) not used in EU.

French hospital pack — Francophone markets

19.4.2004

30049019

COMBIVIR

300/150 mg × 60

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

Distinctive access pack — trilingual text

Bottle (rather than blister pack) ‘A22’ embossed red tablets

30049019

EPIVIR ORAL SOLUTION

10 mg/ml

240 ml

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

Distinctive access pack — trilingual text

19.4.2004

30049019

ZIAGEN

300 mg × 60

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

General export pack — not used in EU.

French hospital pack — Francophone countries

20.9.2004

30049019

RETROVIR ORAL SOLUTION

10 mg/ml

200 ml

GLAXO SMITH KLINE

GSK House

980 Great West Road

BRENTFORD, MIDDX

TW8 9GS

United Kingdom

Distinctive access pack

Trilingual text

20.9.2004

30049019

_______________________



ê 953/2003 (adapted)

ANNEX II

COUNTRIES OF DESTINATION

Afghanistan

Angola

Armenia

Azerbaijan

Bangladesh

Benin

Bhutan

Botswana

Burkina Faso

Burundi

Cambodia

Cameroon

Cape Verde

Central African Republic

Chad

China

Comoros

Congo

Côte d'Ivoire

Ö Democratic Republic of the Congo Õ

Djibouti

 

Equatorial Guinea

Eritrea

Ethiopia

Gambia

Ghana

Guinea

Guinea-Bissau

Haiti

Honduras

India

Indonesia

Kenya

Kiribati

Ö Kyrgyzstan Õ

Ö Laos Õ

Lesotho

Liberia

Madagascar

Malawi

Maldives

Mali

Mauritania

Moldova

Mongolia

Mozambique

Myanmar/Burma

Namibia

Nepal

Nicaragua

Niger

Nigeria

Ö North Korea Õ

Pakistan

Rwanda

Samoa

São Tomé and Príncipe

Senegal

Sierra Leone

Solomon Islands

Somalia

South Africa

Sudan

Swaziland

Tajikistan

Tanzania

Ö Timor-Leste Õ

Togo

Turkmenistan

Tuvalu

Uganda

Vanuatu

Vietnam

Yemen

Zambia

Zimbabwe

_______________________



ANNEX III

PERCENTAGES REFERRED TO IN ARTICLE 3

Percentage referred to in Article 3(a): 25 %

Percentage referred to in Article 3(b): 15 %

_______________________



ANNEX IV

SCOPE OF DISEASES

HIV/AIDS, malaria, tuberculosis and related opportunistic diseases



ANNEX V

LOGO

The winged staff of Aesculapius with a coiled serpent, in the centre of a circle formed by 12 stars.

__________________



é

ANNEX VI

Repealed Regulation with list of its successive amendments

Council Regulation (EC) No 953/2003
(OJ L 135, 3.6.2003, p. 5)

Commission Regulation (EC) No 1876/2004
(OJ L 326, 29.10.2004, p. 22)

Commission Regulation (EC) No 1662/2005
(OJ L 267, 12.10.2005, p. 19)

Regulation (EU) No 38/2014 of the European Parliament and of the Council
(OJ L 18, 21.1.2014, p. 52)

Only point 3 of the Annex

_____________


ANNEX VII

Correlation Table

Regulation (EC) No 953/2003

This Regulation

Articles 1, 2 and 3

Articles 1, 2 and 3

Article 4(1)

Article 4(1)

Article 4(2), introductory wording

Article 4(2), introductory wording

Article 4(2)(i)

Article 4(2)(a)

Article 4(2)(ii)

Article 4(2)(b)

Article 4(2)(iii)

Article 4(2)(c)

Article 4(2)(iv)

Article 4(2)(d)

Article 4(2)(v)

Article 4(2)(e)

Article 4(4)

Article 4(3)

Article 4(5)

Article 4(4)

Article 4(6)

Article 4(5)

Article 4(7)

Article 4(6)

Article 4(8)

Article 4(7)

Article 4(9)

Article 4(8)

Article 5

Article 5

Article 5a

Article 6

Article 6

Article 7

Article 7

Article 8

Article 8

Article 9

Article 9

Article 10

Article 10

Article 11

Article 11

Article 12

Article 12

Article 13

-

Article 14

Article 13

Article 15

Annexes I to V

Annexes I to V

-

Annex VI

-

Annex VII

_____________

(1) Only if applicable.
Top